RESEARCH ARTICLE

Open Access

Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection

Elham Beyranvand Nejad^{1,2†}, Robert B. Ratts^{3†}, Eleni Panagioti^{1,2}, Christine Meyer³, Jennifer D. Oduro⁴, Luka Cicin-Sain^{4,5,6}, Klaus Früh³, Sjoerd H. van der Burg² and Ramon Arens^{1*}

Abstract

Background: The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer vaccine platform. Defined immune thresholds for tumor protection and the factors affecting such thresholds have not well been investigated in cancer immunotherapy. We here determined using CMV as a vaccine platform whether critical thresholds of vaccine-specific T cell responses can be established that relate to tumor protection, and which factors control such thresholds.

Methods: We generated CMV-based vaccine vectors expressing the E7 epitope and tested these in preclinical models of HPV16-induced cancer. Vaccination was applied via different doses and routes (intraperitoneal (IP), subcutaneous (SC) and intranasal (IN)). The magnitude, kinetics and phenotype of the circulating tumor-specific CD8⁺ T cell response were determined. Mice were subsequently challenged with tumor cells, and the tumor protection was monitored.

Results: Immunization with CMV-based vaccines via the IP or SC route eliciting vaccine-induced CD8⁺ T cell responses of > 0.3% of the total circulating CD8 T cell population fully protects mice against lethal tumor challenge. However, low dose inoculations via the IP or SC route or IN vaccination elicited vaccine-induced CD8⁺ T cell responses that did not reach protective thresholds for tumor protection. In addition, whereas weak pre-existing immunity did not alter the protective thresholds of the vaccine-specific T cell response following subsequent immunization with CMV-based vaccine vectors, strong pre-existing immunity inhibited the development of vaccine-induced T cells and their control on tumor progression.

Conclusions: This study highlight the effectiveness of CMV-based vaccine vectors, and shows that demarcated thresholds of vaccine-specific T cells could be defined that correlate to tumor protection. Together, these results may hold importance for cancer vaccine development to achieve high efficacy in vaccine recipients.

Keywords: T cells, Cancer, CMV-based vaccine vector, Pre-existing immunity

* Correspondence: R.Arens@lumc.nl

[†]Elham Beyranvand Nejad and Robert B. Ratts contributed equally to this work.

¹Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
Full list of author information is available at the end of the article

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

The role of the immune system in cancer eradication has been firmly established. Immunotherapy of cancer has set itself as a mainstream therapy among the conventional therapies comprising chemotherapy, radiotherapy and surgery. Adoptive cell therapy (ACT) with tumor-specific T cells and immunotherapeutic approaches in which the inhibitory pathways are blocked or the costimulatory pathways are triggered to invigorate tumor-specific T cells have shown efficacy in a significant number of patients [1, 2]. Vaccination is another promising form of cancer immunotherapy that has been extensively explored, yet few therapeutic vaccines have shown clinical benefit. The latter has been attributed to the lack of inducing substantial long-lasting functional T cell responses that are able to overcome the immunosuppressive environment [3].

Immune thresholds are instrumental to determine vaccine efficacy and effectiveness against pathogens [4]. In cancer immunotherapy, however, tumor protection thresholds and the factors affecting such thresholds have not well been investigated although as such they are instrumental for both practical reasons and mechanistic insights. To elicit and maintain high immune responses, cytomegalovirus (CMV) is considered as a promising vaccine vector. CMV is unique among viruses as chronic infection by this common betaherpesvirus is characterized by high frequencies of virus-specific T cells and antibodies that do not decline after primary infection but remain high or even increase over time in a process termed memory inflation [5–8]. Inflationary T cells are mostly effector-memory (EM)-like in phenotype, remain polyfunctional for life, and are found in both lymphoid organs and tissues [9]. Despite the induction of host immune responses, CMVs are still able to re-infect [10–12]. Based on these properties, together with the ability to engineer the genome of CMV to attenuate the pathogenicity and to express foreign antigens [13], CMV-based vaccines are currently being explored. In mice and non-human primates, CMV-based vaccines have demonstrated significant protection against pathogens including simian immunodeficiency virus (SIV), mycobacterium tuberculosis and Ebola virus [14–18]. Moreover, CMV-based vaccines comprising tumor antigens, including melanoma antigens gp100 and TRP2 [19–22], human prostate-specific antigen (PSA) [23], or model antigens like ovalbumin [22, 24], have shown anti-tumor efficacy in prophylactic and therapeutic mouse models.

Here we studied whether thresholds of vaccine-elicited T cell responses could be determined that relate to the efficacy of such vaccines to protect against tumor progression, and which factors influence these thresholds. Specifically, we investigated the vaccine thresholds of CMV-based vaccine vectors and the impact of inoculum

dosages and routes of infection to achieve tumor protection. Given the high world-wide CMV prevalence, and the fact that pre-existing immunity varies, as evidenced by large variations in the magnitude of CMV-specific T cell responses in the population, ranging from barely detectable to 40% of the memory compartment, we also addressed the impact of pre-existing immunity on the protective thresholds [7]. Defining protection thresholds could be highly relevant in determining correlates of protection, considered as a crucial element in vaccine development as it provides the level of vaccine efficacy in vaccine recipients.

We found that CMV-based vaccines eliciting clearly discernible CD8⁺ T cell responses in the blood (>0.3% of the total CD8 T cell population) fully protected mice against lethal tumor challenge while relatively low responses do not provide protection. Previous exposure to CMV resulting in a weak immune response did not impact vaccine efficacy, however, strong pre-existing immunity hampered the induction of vaccine-induced T cells consequently resulting in loss of tumor protection. The results highlight the premise of CMV-based vaccines, and put forward the potential of such vaccines in halting tumor development based on correlates of protection that are established on careful determination of vaccine-induced immune responses.

Methods

Mice

C57BL/6 mice were obtained from Charles River Laboratories (L'Arbresle, France) or Jackson Laboratory (Sacramento, CA, USA). At the start of the experiments, mice were 6 to 8 weeks old. Mice were housed in individually ventilated cages (IVC) under specific pathogen-free (SPF) conditions in the animal facility of Leiden University Medical Centre (LUMC, The Netherlands) or Oregon Health and Science University (OHSU, Oregon, USA). All animal experiments were approved by the institutional Animal Experiments Committee and were executed according to the institutional animal experimentation guidelines and were in compliance with the guidelines of the Institutional, European and Federal USA animal care and usage committees.

Virus preparation

Viral titers of virus stocks or infected tissues were determined by plaque assays as previously described [25]. MCMV-IE2-E7 (RAHYNIVTF) and MCMV-IE2-OVA (SIINFEKL) were generated as described [26]. MCMV-IE2-E6/E7 full length fusion, MCMV-IE2-E6/E7 full length replace, MCMV-M79-FKBP-E7 (E7 epitope RAHYNIVTF, IE2 fusion), MCMV-M79-FKBP-gB (gB epitope SSIE-FARL, IE2 fusion) were constructed as follows. MCMV BACs were maintained in SW105 *E. coli* and modified by

metabolic galactokinase (*galK*) selection [27], essentially as described [28]. In brief, bacteria containing the MCMV backbone were first transformed with a PCR product of *galK*/kanamycin (*kan*) and flanking homology to target a specific region in the MCMV BAC. Transformed bacteria were selected for *kan* resistance, grown and subjected to a second transformation to replace the *galK/kan* cassette with the final insert. These included annealed oligos used for IE2 peptide fusion or the PCR product for M79-FKBP [29] and HPV E6/E7 insertions containing the desired modification with the same MCMV flanking homology to insert the *galK/kan* cassette. Recombinant bacteria were counter-selected on chloramphenicol 2-deoxy-galactose (DOG) minimal media plates with glycerol as the carbon source. MCMV BAC constructs were characterized by restriction digest, PCR screening, and Sanger and NGS sequencing. Virus was reconstituted by either Lipofectamine 3000 (ThermoFisher Scientific) transfection or electroporation (250 V and 950 μ F) of NIH 3T3s.

Tissue culture-derived stocks of the MCMV vectors were amplified and titered in NIH 3T3 cells grown in complete growth media (DMEM, FBS, PSG). FKBP-tagged viruses were grown in complete growth media supplemented with Shield-1 at a final concentration of 1 μ M and added every 48 h [29]. Cell free virus was obtained from supernatant of infected cells, clarified at 3,000 rpm for 20 min and virus was pelleted at 24,000 rpm for 1 h through a sorbitol cushion (10% D-sorbitol, 0.05 M Tris pH 7.4, 1 mM MgCl_2). Virus pellet was resuspended in PBS. For virus quantification, plaque assays were performed in 24-well plates by infection with appropriate serial virus dilution in 0.2 mL of media and then incubated at 37 °C for 2 h rocking. Following incubation, the infected cells were overlaid with 1 mL complete media supplemented with carboxymethylcellulose. After 5 to 6 days, the cells were fixed in 3.7% formaldehyde in PBS and stained with 0.001% aqueous methylene blue. The plaques were counted by light microscopy. Multi-step virus replication curves were performed in NIH 3T3 cells at MOI 0.1 in 6 well plates, 3 replicates per virus per time-point. Virus was incubated at 37 °C for 2 h, washed 3 times with PBS and then 2 mL of media was added. Supernatant was harvested at 1, 3, 5, and 7 days post-infection, stored at -80 °C and titered by plaque assay. FKBP-tagged viruses were grown in complete growth media supplemented with Shield-1 at a final concentration of 1 μ M and added every 48 h.

Tumor challenge models and anti-tumor vaccination

The tumor cell line TC-1 (a kind gift from T.C. Wu, Johns Hopkins University, Baltimore, MD) was generated by retroviral transduction of C57BL/6 lung epithelial cells with the HPV16 E6/E7 and c-H-ras oncogenes [30]

and cultured as previously described [31]. The tumor cell line C3 was developed by transfection of mouse embryonic cells with the HPV16 genome and an activated-ras oncogene and maintained as previously described [32]. The MC38-OVA tumor cell line is generated by a retroviral infection of the MC38 parental cell-line with PMIG/MSCV-IRES-GFP plasmid encoding cytoplasmic bound OVA [33]. Iscove's Modified Dulbecco's Media (IMDM) (Lonza, Basel, Switzerland) supplemented with 8% fetal calf serum (FCS) (Greiner), 2 mM L-glutamine (Life Technologies, Carlsbad, CA, United States), 50 IU/ml Penicillin (Life Technologies) and 50 μ g/ml Streptomycin (Life Technologies) was used to culture tumor cell lines. Cells were cultured in a humidified incubator at 37 °C and 5% CO_2 . *Mycoplasma* tests that were frequently performed for all cell lines by PCR were negative.

Treatment schedule of experiments are indicated in the respective figures and legends. Mice were vaccinated with MCMV vectors via the intraperitoneal (IP), intranasal (IN) or subcutaneous (SC) route with the indicated inoculum size. In tumor experiments, mice were inoculated subcutaneously in the flank with $0.25-1 \times 10^5$ TC-1 tumor cells, 5×10^5 C3 tumor cells or with 2.5×10^5 MC38-OVA in 200 μ l PBS containing 0.2% BSA on day 0. Tumor size was measured two times a week using a caliper. Mice were euthanized when tumor size reached $> 1000 \text{ mm}^3$ in volume or when mice lost over $> 20\%$ of their total body weight (relative to initial body mass).

In vivo antibody usage

CD8 T cell depleting monoclonal antibodies (clone 2.43) were purchased from Bio-X-Cell (West Lebanon, NH, United States) and administered IP twice weekly (200 μ g/mouse) for 2–3 weeks. CD8 T cell depletion was started 4 days before tumor challenge. Depletion was checked by staining for CD3 and CD8 marker expression followed by flow cytometric analysis.

Flow cytometry

Blood collection and processing was performed as described [34]. Cells were re-suspended in staining buffer (PBS + 2% FCS + 0.05% sodium azide) and incubated with various fluorescently labelled antibodies detecting CD8 (clone 53–6.7), CD62L (clone MEL-14), CD44 (clone IM7), KLRG1 (clone 2F1), CD3 (clone 500A2), CD127 (clone A7R34). Antibodies were obtained from eBioscience (San Diego, CA, United States), BD Biosciences (San Jose, CA, United States) and Biolegend (San Diego, CA, United States). For dead cell exclusion, 7-Aminoactinomycin D (Invitrogen, Carlsbad, CA, United States) was used. To measure the MCMV-specific and tumor antigen-specific T cell responses, PE and APC-labelled class I-restricted multimers (tetramers or dextramers) with the peptide epitopes OVA_{257–264} (SIINFEKL), HPV E7_{49–57} (RAHYNIVTF),

MCMV M45_{985–993} (HGIRNASFI), MCMV M38_{316–323} (SSPPMFRV) were used. Tetramers were produced as described [35] and dextramers were obtained from Immudex. Samples were analyzed with a BD LSRII or LSRFortessa flow cytometer, and results were analyzed using FlowJo software (Tree Star, Ashland, OR, United States).

In vivo cytotoxicity assay

Splenocytes of naïve CD45.1 (Ly5.1) mice were isolated and loaded with MHC class I restricted-E7_{49–57} or OVA_{257–264} peptides for 1 h at 37 °C at the final concentration of 1 µg/ml. After extensive washing, cells which were pulsed with specific peptide or irrelevant peptide were labelled with high and low concentrations of CFSE (Invitrogen), respectively. Next, 5×10^6 peptide pulsed cells were pooled and injected intravenous (IV) via the retro-orbital route into the mice that have been vaccinated 70 days earlier with MCMV-based vaccines. After 24 h, spleens of the recipient mice were isolated, stained for CD45.1, and subjected to flow cytometry. The cytotoxic capacity was calculated relative to naïve mice by using the following formula: $[100 - ((\text{percentage of pulsed peptide in infected mice} / \text{percentage of unpulsed peptide in infected mice}) / (\text{percentage of pulsed peptide in naive mice} / \text{percentage of unpulsed peptide in naive mice})) \times 100]$.

Enzyme-linked ImmunoSpot (ELISpot) assay

Splenocytes of individual vaccinated mice were isolated and cultured on ELISpot plates (R&D systems, Minneapolis MN) pre-coated with anti-IFN-γ antibodies. The indicated peptides (E7_{49–57}, RAHYNIVTF; or a pool of peptides spanning the E7 sequence, 15-mers overlapping by 11) were added at 1 µg/ml. 36 h later cells were removed and secondary antibodies added. Plates were developed according to the manufactures instructions. Spots were counted using an AID ELISpot reader.

Statistical analysis

Statistical analyses were performed using GraphPad Prism (La Jolla, CA, United States). Survival data were analyzed by Kaplan-Meier and the log-rank (Mantel-Cox) test. Statistical significance was determined by Mann Whitney. *P*-values of ≤ 0.05 were considered statistically significant.

Results

Location and size of foreign sequences in CMV-based vaccine vectors impact vaccine-elicited T cell responses and associated tumor protection

To determine effective regions to insert foreign sequences, we generated recombinant MCMV-based vaccine vectors containing the entire E6 and E7 antigens of human papilloma virus type 16 (HPV16). In these vectors the E6/E7 genes replaced exon 3 of IE2 (MCMV-IE2-E6/E7 full

length replace) or E6/E7 was placed in the end part of the IE2 region (MCMV-IE2 E6/E7 full length fusion) (Fig. 1a). To analyze the T cell responsiveness to the inserted foreign sequences induced by these vaccine vectors, we IP vaccinated mice and measured the E7-specific T cell responses by IFN-γ ELISPOT, following restimulation with the immunodominant peptide epitope E7_{49–57} or with a pool of overlapping peptides covering the whole E7 protein, and by staining with MHC class I multimers. Immunization with MCMV-IE2-E6/E7 full length fusion induced significantly higher E7-specific T cell responses (~0.5–2% of the total CD8⁺ T cell population) than MCMV-IE2-E6/E7 full length replace (<0.3%) at 10 and 21 weeks after vaccination (Fig. 1b and c). To assess the anti-tumor immunity induced by these recombinant viruses we challenged the vaccinated mice with TC-1 tumor cells, which are transformed by expression of the HPV16 E6 and E7 oncoproteins [30]. Vaccination with MCMV-IE2-E6/E7 full length fusion prevented tumor progression in most tumor-challenged mice, while the majority of the mice vaccinated with MCMV-IE2-E6/E7 full length replace developed tumors (Fig. 1d). Thus, consistent with our previous report we found that fusion of foreign sequences to the C-terminus of the IE2 protein works superior in eliciting T cell responses, and this event relates to higher amounts of the peptide epitope presented in peptide-MHC complexes [26].

Next, we analyzed the impact of the size of the E6/E7 antigens, and therefore generated a recombinant MCMV expressing only a single immunodominant CD8 T cell epitope, i.e. RAHYNIVTF (E7_{49–57}), fused to the carboxyl terminus of the MCMV IE2 gene (MCMV-IE2-E7). Clearly, mice immunized with MCMV-IE2-E7 resulted in the highest E7-specific T cell response (~2–8%), and vaccination with MCMV-IE2-E7 fully protected mice against otherwise lethal TC-1 tumor challenge (Fig. 1c and d). In conclusion, both the location and size of inserted foreign sequences impact the vaccine-elicited T cell response of MCMV vaccine vectors and this corresponds to protection against tumor outgrowth.

The magnitude of inflationary T cell responses elicited by recombinant MCMV-based vaccine vectors is influenced by the inoculation route and dose and determines vaccine efficacy

To investigate the impact of the route of inoculation on the application of MCMV-based vaccine vectors for vaccine-elicited immunity against cancer, we compared the magnitude and kinetics of the antigen-specific CD8⁺ T cell response in the blood upon IP, IN and SC inoculation. The E7-specific CD8⁺ T cell responses elicited with MCMV-IE2-E7 increased gradually to ~5% after IP immunization, while the responses were steadily

~0.6% after SC inoculation. Upon IN inoculation however, the E7-specific CD8⁺ T cell responses were minute throughout infection (<0.3%) (Fig. 2a and b). The M38_{316–323} epitope-specific CD8⁺ T cell response after IP and SC inoculation showed similar magnitude and kinetics as the response to the E7 epitope in the same vector (Fig. 2a and b). Upon IN immunization, the M38-specific CD8⁺ T cell response was barely detectable and did not show signs of inflation. Upon immunizations via the IP and SC routes, the non-inflationary response to the M45_{985–993} epitope showed the typical response pattern of rapid expansion followed by swift contraction and stable memory formation (Fig. 2a and b). IN vaccination induced only ~0.1% M45-specific

CD8⁺ T cells, and during the memory phase this response was close to the detection limit (Fig. 2a and b).

Characteristic for inflationary T cells is their effector-memory (EM) like (CD44⁺CD62L^{low}, CD127^{+/–}, KLRG1⁺) appearance [6]. Early after IP and SC immunization, the E7-specific CD8⁺ T cell population acquired an EM-like phenotypic profile, which remained high throughout the memory phase (Fig. 2c). The M38-specific CD8⁺ T cells displayed a gradual increase of the EM phenotype to 70–80% of the total Ag-specific T cell population. In contrast, only 40% of the M45-specific CD8⁺ T cells showed an EM phenotype throughout the memory phase. Upon IN immunization, the formation of the EM phenotype by the E7, M38 and M45-specific CD8⁺ T cells was much less

Fig. 2 Vaccination with recombinant MCMV vectors via the IP and SC route induces potent specific T cell responses. Mice were vaccinated with MCMV-IE2-E7 via IP, SC or IN route or kept unvaccinated (control), and the CD8 T cell responses were examined in blood. **a** Representative flow cytometry plots for MHC class I multimer staining to E7, M38 and M45 epitopes in blood of MCMV-IE2-E7 infected mice via IP during acute phase (day 8 post vaccination) and memory phase (day 64 post vaccination). Numbers represent the percentage of Ag-specific CD8⁺ T cells within the total CD8⁺ T cell population. Control flow cytometry plots show the staining for E7 multimer in unvaccinated mice. Flow cytometry plots show similar numbers of total cells in each plot except for control. **b** Frequency of Ag-specific CD8⁺ T cells to E7, M38 and M45 epitopes over time. **c** Frequency of effector-memory (EM) cells (KLRG1⁺, CD62L⁺) within E7, M38 and M45 MHC multimer⁺ CD8⁺ T cells over time. Data represents mean values $\pm$ SEM ($n = 7-8$ mice per group) and are representative of two independent experiments with similar results

pronounced (Fig. 2c). Taken together, these data show that immunization with recombinant MCMV vectors via the IP and SC route induces prominent EM-like CD8⁺ T cell responses, albeit with different kinetics, while IN infection resulted in weak responses at best.

Next, we investigated the influence of the route of immunization and the resulting vaccine-specific T cell response elicited by the MCMV vectors on efficacy in tumor challenge experiments. We vaccinated mice with MCMV-IE2-E7 via the IP, IN or SC routes and challenged these mice with TC-1 tumor cells. While TC-1

tumors grew out progressively in all naïve mice, immunization with MCMV-IE2-E7 via the IP and SC route induced complete protection against TC-1 tumor challenge (Fig. 3a). Conversely, IN immunization with MCMV-IE2-E7 protected only 50% of the mice (Fig. 3a). Notably, the IN immunized mice that were protected had stronger E7-specific CD8⁺ T cell responses as compared to the unprotected group (Fig. 3b). Thus, MCMV vectors inducing circulating tumor-specific CD8⁺ T cell responses $> 0.3\%$ provides full protection while responses below this threshold results in loss of protection. Immunizations with

MCMV-based vaccine vectors via routes of vaccination that induce large tumor-specific T cell responses are thus superior in controlling tumor outgrowth. In addition, all the mice which remained tumor free until day 60, including the subset of the IN vaccinated mice, were protected against challenge with C3 tumor cells expressing HPV antigens including the E7 oncoprotein (Fig. 3c). Protection against MC38 tumor cells, which do not express E7, was however not established (data not shown). These results also indicate the induction of immunological memory including in those mice vaccinated via the IN route.

To assess the capacity of CMV-based vaccines to elicit responses to other inserted foreign epitopes, we tested MCMV expressing the H-2Kb-restricted OVA_{257–264} (SIINFEKL) epitope from ovalbumin (OVA). Immunization with MCMV-IE2-OVA induced OVA-specific CD8⁺ T cell

responses against OVA_{257–264} that were slightly higher than the response against E7 after MCMV-IE2-E7 immunization. The responses against the epitopes in M38 and M45 were similar (Additional file 1: Figure S1A). Moreover, vaccination with MCMV-IE2-OVA induced complete protection against OVA-expressing MC38 tumor cells (Additional file 1: Figure S1B).

Next, we examined whether tumor protection was solely due to the induction of tumor-specific T cell responses or whether possible bystander effects of virus infection were implicated. First, we established the requirement of CD8⁺ T cells in the tumor protective role of MCMV-based vaccine vectors. CD8⁺ T cell depletion 4 days before TC-1 tumor challenge in mice immunized earlier with MCMV-IE2-E7 via the IP route resulted in tumor progression, which underscores the importance of

CD8⁺ T cells (Fig. 4a). Second, mice inoculated with MCMV-IE2-OVA and challenged with TC-1 tumor cells, which do not express OVA antigen, were not protected whereas MCMV-IE2-OVA immunization protects against MC38-OVA (Fig. 4a and b). Vice versa, MCMV-IE2-E7 immunization does not provide protection against MC38-OVA (Fig. 4b), while this vaccine vector

provides protection against E7-expressing TC-1 tumor cells (Figs. 3a, 4a). To further demonstrate specific target-mediated killing induced by the MCMV-based vaccine vectors, we performed in vivo cytotoxicity assays. Target cells pulsed with vaccine-specific antigen or control antigen were injected into mice previously vaccinated with MCMV-IE2-E7 (Fig. 4c) or MCMV-IE2-OVA (Fig. 4d).

Fig. 4 Specific anti-tumor immunity elicited by MCMV-based vaccine vectors is essential for protection. **a** TC-1 tumor outgrowth of unvaccinated mice and of mice previously vaccinated with MCMV-IE2-E7 or MCMV-IE2-OVA via the IP route. CD8 depleting antibody was given in the group of mice vaccinated with MCMV-IE2-E7 via IP starting 4 days before tumor challenge. The number of tumor-free/total mice is indicated in each graph. Data was pooled from two independent experiments. **b** MC38-OVA tumor outgrowth of unvaccinated mice and of mice previously vaccinated with MCMV-IE2-E7 or MCMV-IE2-OVA via the IP route. The number of tumor-free/total mice is indicated in each graph. Data are representative of two independent experiments with similar results. **c** and **d** Representative histograms of CTL-mediated killing responses induced by MCMV-IE2-E7 (**c**) or MCMV-IE2-OVA (**d**). Mice were vaccinated with 5×10^5 PFU MCMV-IE2-E7 (**c**) or MCMV-IE2-OVA (**d**) via SC. After 69 days, splenocytes from naïve mouse were pulsed with specific peptide; E7₄₉₋₅₇ (**c**) or OVA₂₅₇₋₂₆₄ (**d**) or unspecific peptide and labelled with high and low concentrations of CFSE, respectively. Then, cells were adoptively transferred to the MCMV vaccinated mice or naïve mice as control. One day later, spleens of the mice were analyzed for the percentage of killing as described in materials and methods

Both MCMV-based vaccine vectors induced exclusive killing of target cells presenting the vaccine-specific antigen. Thus, vaccine-induced specific CD8⁺ T cell responses against antigens expressed by the tumor are required to induce protective immunity and responses against the vector alone do not provide protection.

To substantiate whether the magnitude of the circulating vaccine-specific CD8⁺ T cell response relates to tumor protection, we IP and SC immunized mice with low inoculum dosages to achieve responses below the 0.3% threshold (Fig. 5a). Infection with a high dose of MCMV-IE2-E7 via the IP and SC route induced as expected stronger CD8⁺ T cell responses (>0.3%) against the E7 epitope compared to inoculum dosages with 1000 fold less virus, which resulted in responses <0.3% in the blood (Fig. 5b). The higher response in magnitude correlated to a higher percentage of EM-like phenotype within the total Ag-specific CD8⁺ T cell population (Fig. 5b). Importantly, immunization with high dose MCMV-IE2-E7 via the IP and SC route protected mice from tumor outgrowth (Fig. 5c and d, Group 2 and 3) while immunization with the low dose resulted in less protection (Fig. 5c and d, Group 5 and Group 6). In the SC but not in the IP low-dose immunized group some mice were protected despite circulating E7-specific CD8⁺ T cells below the threshold. Furthermore, similar to the data shown in Fig. 3 IN immunization with 1×10^5 PFU MCMV-IE2-E7 elicited a response of ~0.3%, and resulted in partial protection (40% survival) (Fig. 5a-d, Group 4). Again, the IN immunized mice that were protected had E7-specific CD8⁺ T cell responses >0.3% while the unprotected group had responses <0.3% (data not shown). When a 200 fold lower vaccine dose (500 PFU) for the IN route was used, which elicited a lower response (~0.1%), all the mice succumbed to the tumor challenge (Fig. 5a-d, Group 7). Taken together, these data indicate that the magnitude and EM phenotype of the vaccine-induced CD8⁺ T cells are controlled by the route of vaccination and inoculum dosage, and are principal determinants for the efficacy of MCMV-based vaccine vectors against tumors.

Immunity to re-infection can hamper the formation of vaccine-induced CD8⁺ T cell responses

Although CMV has the capacity to re-infect the host despite the presence of CMV-specific T and B cell responses elicited upon primary infection, CMV-specific immunity clearly controls viral pathogenesis of primary and secondary infections as shown by the fact that CMV mainly causes disease in immature or immunocompromised situations, and pre-existing immunity strongly limits viremia upon secondary infection [11, 12]. To address the impact of pre-existing MCMV immunity on vaccine-induced CD8⁺ T cell responses and hence the

induction of protective immunity, we examined the kinetics of the MCMV vaccine-specific T cell responses in different settings of pre-existing immunity. To mimic the condition of pre-existing immunity in the TC-1 tumor challenge setting, we infected mice first with MCMV-IE2-OVA, which provokes pre-existing immunity but does not elicit tumor-specific T cell immunity. After the establishment of pre-existing immunity, mice were vaccinated with MCMV-IE2-E7. This experimental setup allowed us to follow the antigen-specific T cell response following the first infection and after the subsequent immunization, in which a) the OVA-specific T cell response is primary after the infection and not boosted, b) the M38-specific CD8⁺ T cell response is primary after the infection and then boosted by the immunization, and c) the E7-specific T cell response (which is tumor-specific in case of TC-1 tumor challenge) is not induced during the first infection, hence is primary upon the immunization. Here, we confirmed that IP infection with MCMV-OVA induces higher OVA and M38-specific CD8⁺ T cell responses (~5% OVA and ~1.5 M38) in blood (Fig. 6a) compared to infection via IN (~0.5% OVA and ~0.4% M38). Next, we investigated the E7 (tumor)-specific T cell response in these high (IP) and low levels (IN) of pre-existing immunity. Vaccination with MCMV-IE2-E7 via the IP and SC route boosted the M38-specific T cell response (~3% M38 compared to 1.5 and 0.5% after primary infection) and this increase was more pronounced in the mice with low pre-existing immunity compared to high pre-existing immunity. Importantly, a higher E7-specific T cell response was also determined in the mice with low pre-existing immunity (0.7–1% versus 0.3%) (Fig. 6a). The CD8⁺ T cell response against the OVA_{257–264} epitope did not change upon subsequent immunization with MCMV-IE2-E7. Together, these data suggest that super-infection occurs more readily upon primary inoculation via the IN route versus the IP route. Moreover, the level of pre-existing immunity affects the magnitude of the T cell responses elicited to MCMV vectored antigens.

To assess how various levels of pre-existing MCMV immunity influence the tumor protection, mice with low and high pre-existing immunity were challenged with TC-1 tumor cells (Fig. 6b and c). Mice with a high level of pre-existing immunity (infected previously with a high dose MCMV-IE2-OVA via the IP route) and vaccinated IP, SC or IN with MCMV-IE2-E7 were not protected (Fig. 6b and c, Group 4, 5 and 6). This correlated with the elicited E7-specific responses in the blood that were <0.3%, except for one mouse in group 5 (SC vaccinated) which cleared the tumor and correspondingly had an E7-specific CD8⁺ T cell responses >0.3% (Fig. 6a and d). Moreover, infection with a 1000 fold lower inoculum dosage of MCMV-IE2-OVA via the IP route followed by

Fig. 5 The inoculum dosage of recombinant MCMV-based vaccine vectors determines the magnitude of anti-tumor T cell response and protection efficacy. **a** Schematic of the experiment. Mice were infected with indicated doses and routes or kept unvaccinated. After 35 days, all the mice were challenged with TC-1 tumor cells. The tumor outgrowth and survival of the mice was followed for 60 days. **b** Percentage of E7-specific and the percentage of EM-like cells within the E7-specific CD8⁺ T cells of the vaccinated mice. **c** and **d** TC-1 tumor outgrowth (**c**) and survival (**d**) graphs of mice immunized with MCMV-IE2-E7 (schematic shown in **a**). The number of tumor-free/total mice is indicated above each tumor out growth graph in **(c)**. Tumor out growth was followed for 60 days. The number of tumor-free/total mice is indicated. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$

Fig. 6 (See legend on next page.)

(See figure on previous page.)

Fig. 6 Pre-existing immunity against the MCMV vector affects the strength of T cell responses and anti-tumor efficacy. **a** Percentage of OVA, M38 and E7-specific CD8⁺ T cells, identified using MHC class I multimers. Mice were infected with 1×10^5 PFU via IP or IN MCMV-IE2-OVA at day 0. After 35 days, the mice were vaccinated with 1×10^5 PFU MCMV-IE2-E7 via IP route or with 5×10^5 MCMV-IE2-E7 via the SC route as shown in the schematic. T cell responses were followed for 70 days in blood. Data represent mean values $\pm$ SEM. **b** and **c** Tumor outgrowth (**b**) and survival (**c**) of mice infected with 1×10^5 PFU MCMV-IE2-OVA via IP or IN and vaccinated with 1×10^5 PFU MCMV-IE2-E7 via IP or IN route or with 5×10^5 MCMV-IE2-E7 via SC as shown in the schematic. After 70 days, all the vaccinated and control mice were challenged with 1×10^5 TC-1 tumor cells. The number of tumor-free/total mice is indicated above each tumor outgrowth graph. **d** The percentage of E7-specific CD8⁺ T cells within the total CD8⁺ T cell population in the blood (y-axis) plotted against the E7-specific CD8⁺ T cell response ranked from low to high (x-axis) of the mice that were either tumor-free (tumor-) or tumor positive (tumor+). Data are representative of two independent experiments with similar results

IP vaccination with MCMV-IE2-E7 resulted in partial protection (Fig. 6b and c, Group 7). Remarkably, the unprotected mice in this group had E7-specific CD8⁺ T cell responses $< 0.3\%$ while all protected mice had responses $> 0.3\%$ (Fig. 6d). Moreover, in mice infected with MCMV-IE2-OVA via the IN route and then vaccinated with MCMV-IE2-E7 via the IP and SC route, none of the tumors grew out and the mice remained tumor-free (Fig. 6b and c, Group 2 and 3). Importantly, these mice had E7-specific CD8⁺ T cell responses in the blood $> 0.3\%$ (Fig. 6a and d). Taken together, these data indicate that the level of pre-existing immunity can set the protection threshold of vaccine-induced CD8⁺ T cell responses by CMV-based vaccine vectors: a strong T cell response against the vaccine vector elicited during primary infection inversely correlates with the ability of an MCMV-vectored vaccine to elicit protective immunity upon super-infection.

Single-cycle replication is sufficient for the anti-tumor efficacy of MCMV based vaccine vectors

Non-attenuated CMV may cause disease in immunosuppressed individuals. To facilitate the translation of CMV-based vaccine vectors into the clinic, we generated an attenuated E7-epitope-expressing MCMV vector by fusing the FKBP-degradation domain to the essential M79 protein (MCMV-M79-FKBP-E7), which restricts viral replication to a single-cycle in absence of the stabilizing ligand Shield-1 similar to corresponding HCMV FKBP constructs targeting the homologous UL79 gene (Additional file 2: Figure S2). Vaccination with the spread-deficient MCMV-M79-FKBP-E7 elicited E7-specific CD8⁺ T cell responses that were $> 0.5\%$ of the total CD8⁺ T cell population at 4 weeks and even up to 13 months after vaccination (Fig. 7a and b). In addition, the E7-specific CD8⁺ T cells displayed an EM phenotype at late time-points post immunization (Fig. 7c). IP immunization with MCMV-M79-FKBP-E7, but not with a control single-cycle virus expressing the immunodominant HSV gB epitope (MCMV-M79-FKBP-gB), prevented TC-1 tumor progression at 4 weeks, 21 weeks and 13 months post-vaccination indicating long-lasting specific anti-tumor immunity (Fig. 7d). In a similar fashion, MCMV-M79-FKBP-E7 vaccination prevented outgrowth

of C3 and TC-1 tumors in most mice (Fig. 7e, Additional file 3: Figure S3A and data not shown). Low level pre-existing immunity elicited via IN infection with MCMV-IE2-OVA did not impact the anti-tumor efficacy of MCMV-M79-FKBP-E7 (Fig. 7e). In mice that succumbed to the tumor challenge, the E7-specific CD8⁺ T cell responses were all $< 0.3\%$, while all (except one) of the protected mice had responses $> 0.3\%$ (Fig. 7f).

To investigate the efficacy of MCMV-based vaccine vectors in therapeutic settings, we challenged naïve mice with TC-1 tumor cells followed by vaccination when tumors were palpable. Tumor-bearing mice vaccinated with MCMV-IE2-E7 and with MCMV-M79-FKBP-E7 via the IP and SC route resulted in substantial suppression of tumor outgrowth (Fig. 7g and Additional file 3: Figure S3B). Together these data indicate that a single-cycle MCMV-based vector could offer a safe vaccine platform to induce effective anti-tumor CD8⁺ T cell responses in prophylactic and therapeutic settings.

Discussion

Here we interrogated whether vaccination thresholds based on the level of tumor-specific T cells elicited by CMV-based vaccines can be sharply defined in order to provide correlates of protection. In addition, we examined the critical factors impacting on the protection threshold and hence the efficacy of CMV-based vaccines against cancer. Fundamentally, we found that CMV-based vaccine vectors have the capacity to provide long-lasting tumor-specific T cell responses that protect against tumors, provided that such responses reach a defined threshold.

CMV-based vectors are thus able to generate defined thresholds of circulating vaccine-specific CD8 T cells that provide long-lasting tumor protection. The factors that determine this threshold such as virus dose, route of vaccination and pre-existing immunity have to be extensively studied to consider the development of effective CMV-based vaccines in cancer patients. CMVs are large viruses (> 230 Kb) encoding more than 170 proteins. Although large viral vaccine vectors eliciting strong T cell responses could possibly lead to competition for antigen-presentation and “space”, which may

Fig. 7 (See legend on next page.)

(See figure on previous page.)

Fig. 7 Single cycle replication of MCMV based vector vaccine is sufficient to induce anti-tumor effects in prophylactic and therapeutic settings.

a. Mice were vaccinated IP with 1×10^6 PFU MCMV-M79-FKBP-E7 or control virus (MCMV-M79-FKBP-gB). Splenocytes were harvested 4, 21 weeks and 13 months after vaccination and stimulated with dominant peptide of E7 or pooled E7 peptides for 36 h (**a**). IFN- γ production was measured by ELISPOT assay. Shown is the number of spots per 5×10^5 cells $\pm$ SEM. **b** Frequency of E7₄₉₋₅₇-specific CD8⁺ T cells within total CD8⁺ T cell population at 4, 21 weeks and 13 months post vaccination. Data represents mean values $\pm$ SEM ($n = 5$ mice per group). **c** KLRG1 and CD127 marker expression on E7-specific CD8⁺ T cells at day 7 and 60 post vaccination with MCMV-M79-FKBP-E7. **d** TC-1 tumor outgrowth of the mice that were vaccinated with 1×10^6 PFU MCMV-M79-FKBP-E7 or control virus MCMV-M79-FKBP-gB at 4, 21 weeks and 13 months before tumor challenge. Tumor out growth was followed for 23 or 40 days. **e** and **f** C3 tumor outgrowth of the mice were infected with 1×10^5 PFU MCMV-IE2-OVA via IN route or kept uninfected. After 35 days, the mice were vaccinated with 1×10^6 PFU MCMV-M79-FKBP IP or kept unvaccinated. Mice were challenged with C3 tumor cells after 35 days. Tumor outgrowth was followed for 60 days (**e**). The number of tumor-free mice from the total mice is indicated above each tumor out growth graph. **f** The percentage of E7-specific CD8⁺ T cells within the total CD8⁺ T cell population in the blood (y-axis) plotted against the E7-specific CD8⁺ T cell response ranked from low to high (x-axis) of the mice that were either tumor-free (tumor-) or tumor positive (tumor+) (**f**). **g** Mice were challenged with TC-1 tumor cells, and after 8 days when tumors were palpable mice were treated with 1×10^6 PFU MCMV-m79-FKBP-E7 or control virus MCMV-m79-FKBP-gB via IP, 1×10^5 PFU MCMV-IE2-E7 via IP or 5×10^5 PFU MCMV-IE2-E7 via SC or kept unvaccinated. Tumor out growth was followed for 40 days. The number of tumor-free mice from the total mice is indicated. Data are representative of two independent experiments with similar results

limit additional T cell responses, this seems not to hamper vaccine-specific T cell responses elicited by CMV. Both in mice and monkeys, CMVs have shown to be very potent inducers of T cell responses to antigens in SIV, Mycobacterium tuberculosis, Ebola [14–18] and several cancers including melanoma, prostate cancer and HPV⁺ cancer (unpublished data Klaus Früh). With respect to space limitation for effector-memory T cells. There is evidence in mice and human that superinfections are able to add more T cells to the memory pool [36, 37]. Although, the percentage of a given T cell population can decrease when more memory T cells are added to the memory pool the absolute numbers of a given T cell population generally does not reduce.

Defined thresholds for protection based on disease-specific T cells have been scarcely reported. Schmidt et al. reported that protection against malaria required a large threshold in memory CD8 T cell frequencies, i.e. > 1% specific T cells of the total CD8⁺ T cell population in blood [38]. Here we found that a threshold of > 0.3% specific blood CD8⁺ T cells links to full tumor protection. The sharp threshold we observed suggest that the elicited tumor-specific T cells have a controlled capacity to kill target cells, which is in line with studies showing that the in vivo killing capacity of CD8⁺ T cells is marked yet restricted [39]. This demarcated threshold is clearly reached upon vaccination with high dose inoculums of MCMV vectors delivered via the IP and SC route, and protects against the development of subcutaneous tumors. On the other hand, immunization via the IN route, considered as a natural route of infection [40], resulted in minor vaccine-specific responses and hence lower protection. However, IN immunization was superior in protection against respiratory pathogens compared to IP immunization due to enhanced induction of tissue-resident memory (TRM) T cells [41]. It is thus conceivable that lung tumors are better controlled following vaccination via the IN route. In

line with this are the observations that upon SC immunization some mice (10–30%) are protected despite that the tumor-specific CD8⁺ T cell response in the blood is below the threshold. In these mice, the SC immunization may have led to induction of skin TRM cells, known to be able to provide tumor protection [42].

Besides the quantity it is expected that the phenotype of the elicited cells is of influence for the effectivity. Inflating or indefinitely maintained CMV-elicited T cell populations are characterized by their progressive EM-like phenotype [43, 44] and such responses seem to be qualitatively different from CM T cells with respect to their immediate effector functions and tissue homing properties [45]. These features are important for protection against viruses at their sites of entry or reactivation, and may as well be crucial for clearance of tumors arising e.g. from epithelial or endothelial cells, or metastasis. Here and also reported elsewhere [46] a correlation between the magnitude and phenotype was observed. The combination of phenotype with magnitude provides a better predictor for protective thresholds than either parameter alone.

We found that high levels of pre-existing immunity elicited by SC or IP immunization hamper the development of vaccine-specific T cell responses due to anti-vector immunity thereby reducing the efficacy of MCMV-based vaccine vectors. In contrast, induction of pre-existing immunity by the natural IN route enables sufficient formation of vaccine-specific T cells upon re-inoculation leading to tumor protection. In support of the conclusion that CMVs can overcome natural immunity is also the observation that strains of HCMV have been reported to frequently re-infect seropositive individuals [47, 48]. Moreover, naturally infected seropositive rhesus macaques can be readily re-infected with rhesus CMV (RhCMV) even when given SC at very low dose [49]. Also, RhCMV/SIV vector-immunized monkeys can be repeatedly re-infected via the SC route [50]. In this animal model, the

ability to re-infect has been shown to be in part due to the effective inhibition of MHC-I antigen presentation [49]. It may be possible to engineer recombinant HCMV vectors that are able to induce strong and protective immune responses despite pre-existing immunity. For rhesus macaques it was already shown that RhCMV vectors containing SIV antigens provide strong vector-elicited T cell immunity and protection against highly virulent SIV challenge in CMV positive animals [50]. Interestingly, the specific vaccine vectors used in these challenge experiments were highly unusual in their T cell targeting phenotype since they elicited CD8⁺ T cells recognizing epitopes presented by MHC class II and MHC-E molecules [51]. Unconventional T cell priming was in part due to conserved MHC class I evasion mechanisms and in part the result of spontaneous genetic changes that occurred in the vectors due to passaging in fibroblasts. However, fibroblast-adapted HCMV-based vaccines did neither elicit HCMV-typical strong effector memory T cell responses nor were the responses unconventional suggesting that unconventional T cell priming is the result of specific mutations that occurred in fibroblasts-adapted RhCMV, but not HCMV [52]. It remains thus to be determined whether HCMV vectors can be engineered both to overcome strong pre-existing immunity and to elicit the desired CD8 T cell response, be it conventional or unconventional, required for protection against specific infectious diseases or cancer. Alternatively, MCMV-based vectors might be used in the clinic as human cells can be abortively infected, still leading to expression and presentation of virally vectored genes [53, 54].

Synthetic vaccines and other viral vectors (than CMV-based such as recombinant vaccinia virus) eliciting T cell responses to the HPV-16 tumor antigens E6/E7 have also been extensively studied [31, 55–60], and some of these vaccines have also shown effectiveness in the clinic [61–63]. Although long-lasting responses with some of these vaccines were accomplished (especially after boosting), the percentage of circulating HPV-specific CD8⁺ T cell responses seemed to be lesser as compared to the responses elicited by MCMV-IE2-E7 as reported here. Whether CMV-based vaccines are effective in patients still needs to be determined, and to accomplish this additional testing is required. A single high-dose vaccination may already be sufficient given the potential induction of large vaccine-specific CD8⁺ T cell responses. Booster regimens with the same CMV-based vectors in therapeutic settings may not work because of high-levels of pre-existing immunity and/or acquired tumor cell resistance after the initial immunization [3]. Yet given their promising results in experimental models an endeavour to test CMV-vectors in the clinic is worth pursuing.

In conclusion, we show that protective thresholds upon immunization with MCMV vectors can be sharply defined via determination of tumor-specific CD8 T cells in blood, and that the inoculum dosage and route of infection are crucial elements determining the magnitude of these cells. In addition, our study shows the importance of determining the level of pre-existing immunity for CMV-based vaccines and suggests including stratification based on the magnitude of CMV-specific T cell responses in pre-vaccinated individuals. The route and dose of immunization may then even be adjusted to improve the vaccine efficacy. Further studies will be needed with the anticipation to improve the efficacy of CMV-based vaccines.

Additional files

Additional file 1: Figure S1. Immunization with MCMV-IE2-OVA induces vaccine-specific CD8⁺ T cell responses. (A) Mice were infected with 1×10^5 PFU MCMV-IE2-OVA via IP or 5×10^5 via SC. Frequency of antigen-specific CD8⁺ T cells for the M45 and M38 epitopes of MCMV and of the inserted OVA antigen were identified using MHC class I multimers. Data represents mean values $\pm$ SEM ($n = 6$ mice per group). Data are representative of two independent experiments. (B) MC38-OVA tumor outgrowth of unvaccinated mice and of mice previously vaccinated with MCMV-IE2-OVA via the IP or SC route. Mice were vaccinated with 1×10^5 PFU MCMV-IE2-OVA via IP or 5×10^5 via SC. After 35 days (MCMV-IE2-OVA IP) or 70 days (MCMV-IE2-OVA SC), mice were challenged with 2.5×10^5 MC38-OVA tumor cells. The tumor outgrowth was followed for 100 days. The number of tumor-free/total mice is indicated in each graph. Data are representative of two independent with similar results. (EPS 1218 kb)

Additional file 2: Figure S2. Fusion of the FKBP-degradation domain to the essential gene M79 results in a single cycle MCMV. Schematic diagram of the construct. The FKBP degradation domain was fused in frame to the N-terminus of M79 via BAC recombination (MCMV-M79-FKBP-E7). In the presence of the small molecule Shield1 the fusion protein is stabilized and virus production occurs. In the absence of Shield1 M79 is degraded and virus production is halted since M79 is essential for late gene expression. (EPS 1463 kb)

Additional file 3: Figure S3. Single cycle replication of MCMV based vectors induces anti-tumor effects. (A) Survival of the mice which were infected with 1×10^5 PFU MCMV-IE2-OVA IN or kept uninfected. After 35 days, the mice were vaccinated with 1×10^6 PFU MCMV-M79-FKBP IP or kept unvaccinated. Mice were challenged with C3 tumor cells after 35 days. Survival was followed for 60 days. (B) Survival of the mice which were challenged with TC-1 tumor cells, and after 8 days when tumors were palpable mice were treated with 1×10^6 PFU MCMV-M79-FKBP-E7 or control virus MCMV-M79-FKBP-gB via IP, 1×10^5 PFU MCMV-IE2-E7 via IP or 5×10^5 PFU MCMV-IE2-E7 via SC or kept unvaccinated. Survival growth was followed for 60 days. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. (EPS 1213 kb)

Abbreviations

ACT: Adoptive cell therapy; CD: Cluster of differentiation; CMV: Cytomegalovirus; DMEM: Dulbecco's Modified Eagle's medium; EM: Effector-memory; FBS: Fetal bovine serum; FCS: Fetal calf serum; galK: Galactokinase; HCMV: Human cytomegalovirus; HPV: Human papilloma virus; IFN- γ : Interferon gamma; IMDM: Iscove's Modified Dulbecco's Media; IN: Intranasal; IP: Intraperitoneal; IV: Intravenous; IVC: Individually ventilated cages; kan: kanamycin; MCMV: Murine cytomegalovirus; OVA: Ovalbumin; PFU: Plaque-forming unit; PSG: Penicillin, streptomycin, glutamine; RhCMV: Rhesus cytomegalovirus; SC: Subcutaneous; SPF: Specific pathogen-free; TRM: Tissue-resident memory

Acknowledgements

The authors acknowledge Suzanne Welten and Anke Redeker for advice and practical help. The authors would like to thank Jan Wouter Drijfhout and Kees Franken for constructing tetramers.

Funding

This work was supported by a grant from Leiden University Medical Center (LUMC; E. Beyranvand Nejad), and a Gisela Thier grant from LUMC (R. Arens).

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its Additional files].

Authors' contributions

EB, RB, KF, SB and RA contributed to the study concepts and study design. Data acquisition was performed by EB, RB, EP, CM, JO. All the authors contributed to the quality control data, analysis and interpretation of data. The manuscript preparation was performed by EB and RA and edited by all authors. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the institutional Animal Experiments Committee and were executed according to the institutional animal experimentation guidelines and were in compliance with the guidelines of the Institutional, European and Federal USA animal care and usage committees.

Consent for publication

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. ²Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. ³Vir Biotechnology, Portland, OR, USA. ⁴Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. ⁵Institute for Virology, Hannover Medical School, Hannover, Germany. ⁶German Centre for Infection Research (DZIF), Partner site, Hannover/Braunschweig, Germany.

Received: 18 September 2018 Accepted: 8 January 2019

Published online: 31 January 2019

References

- Redeker A, Arens R. Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. *Front Immunol*. 2016;7:345.
- Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015;348(6230):56–61.
- van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. *Nat Rev Cancer*. 2016;16(4):219–33.
- Plotkin SA. Vaccines: correlates of vaccine-induced immunity. *Clin Infect Dis*. 2008;47(3):401–9.
- Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski UH, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. *J Immunol*. 2003;170(4):2022–9.
- O'Hara GA, Welten SP, Klenerman P, Arens R. Memory T cell inflation: understanding cause and effect. *Trends Immunol*. 2012;33(2):84–90.
- Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Rucht F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. *J Exp Med*. 2005;202(5):673–85.
- Welten SP, Redeker A, Toes RE, Arens R. Viral persistence induces antibody inflation without altering antibody avidity. *J Virol*. 2016;90(9):4402–11.
- Klenerman P, Oxenius A. T cell responses to cytomegalovirus. *Nat Rev Immunol*. 2016;16(6):367–77.
- Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. Cytomegalovirus reinfections in healthy seroimmune women. *J Infect Dis*. 2010;201(3):386–9.
- Trgovcich J, Kincaid M, Thomas A, Griessl M, Zimmerman P, Dwivedi V, et al. Cytomegalovirus Reinfections Stimulate CD8 T-Memory Inflation. *PLoS One*. 2016;11(11):e0167097.
- Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. *Rev Med Virol*. 2007;17(4):253–76.
- Borst EM, Benkartek C, Messerle M. Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses. *Curr Protoc Immunol*. 2007; Chapter 10:Unit.
- Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. *Nature*. 2011;473(7348):523–7.
- Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. *PLoS Negl Trop Dis*. 2011;5(8):e1275.
- Beverley PC, Ruzsics Z, Hey A, Hutchings C, Boos S, Bolinger B, et al. A novel murine cytomegalovirus vaccine vector protects against *Mycobacterium tuberculosis*. *J Immunol*. 2014;193(5):2306–16.
- Marzi A, Murphy AA, Feldmann F, Parkins CJ, Haddock E, Hanley PW, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. *Sci Rep*. 2016;6:21674.
- Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, et al. Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. *Nat Med*. 2018;24(2):130–43.
- Erkes DA, Xu G, Daskalakis C, Zurbach KA, Wilski NA, Moghbeli T, et al. Intratumoral infection with murine cytomegalovirus synergizes with PD-L1 blockade to clear melanoma lesions and induce long-term immunity. *Mol Ther*. 2016;24(8):1444–55.
- Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. *Biochem Biophys Res Commun*. 2013;437(2):287–91.
- Benonis H, Sow HS, Breukel C, Claessens JWC, Brouwers C, Linssen MM, et al. FcγRIII expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. *Oncotarget*. 2018;9(50):29392–402.
- Qiu Z, Huang H, Grenier JM, Perez OA, Smilowitz HM, Adler B, et al. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8(+) T-cell response and protects mice from melanoma. *Cancer Immunol Res*. 2015;3(5):536–46.
- Klyushnenkova EN, Kouivskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, et al. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. *J Immunother*. 2012;35(5):390–9.
- Tsan T, Vukovic K, Filipovic P, Brizic AL, Lemmermann NAW, Schober K, et al. Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8(+) T cells. *Eur J Immunol*. 2017;47(8):1354–67.
- Welten SP, Redeker A, Franken KL, Benedict CA, Yagita H, Wensveen FM, et al. CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection. *J Virol*. 2013;87(12):6851–65.
- Dekhtiarenko I, Ratts RB, Blatnik R, Lee LN, Fischer S, Borkner L, et al. Peptide processing is critical for T-cell memory inflation and may be optimized to improve immune protection by CMV-based vaccine vectors. *PLoS Pathog*. 2016;12(12):e1006072.

27. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.* 2005;33(4):e36.
28. Dekhtiarenko I, Jarvis MA, Ruzsics Z, Cicin-Sain L. The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens. *J Immunol.* 2013;190(7):3399–409.
29. Perng YC, Qian Z, Fehr AR, Xuan B, Yu D. The human cytomegalovirus gene UL79 is required for the accumulation of late viral transcripts. *J Virol.* 2011; 85(10):4841–52.
30. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. *Cancer Res.* 1996;56(1):21–6.
31. van Duikeren S, Fransen MF, Redeker A, Wiele B, Platenburg G, Krebber W-J, et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. *J Immunol.* 2012;189(7):3397–403.
32. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, De Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. *Eur J Immunol.* 1993;23(9):2242–9.
33. Redeker A, Welten SP, Baert MR, Vloemans SA, Tiemessen MM, Staal FJ, et al. The quantity of autocrine IL-2 governs the expansion potential of CD8+ T cells. *J Immunol.* 2015;195(10):4792–801.
34. Arens R, Loewendorf A, Redeker A, Sierro S, Boon L, Klennerman P, et al. Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations. *J Immunol.* 2011;186(7):3874–81.
35. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JL, et al. Phenotypic analysis of antigen-specific T lymphocytes. *Science.* 1996;274(5284):94–6.
36. van Leeuwen EM, Koning JJ, Remmerswaal EB, van BD, van Lier RA, ten Berge IJ. Differential usage of cellular niches by cytomegalovirus versus EBV- and influenza virus-specific CD8+ T cells. *J Immunol* 2006;177(8):4998–5005.
37. Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, Antia R, et al. Memory CD8 T-cell compartment grows in size with immunological experience. *Nature.* 2009;457(7226):196–9.
38. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. *Proc Natl Acad Sci U S A.* 2008;105(37):14017–22.
39. Halle S, Keyser KA, Stahl FR, Busche A, Marquardt A, Zheng X, et al. In vivo killing capacity of cytotoxic T cells is limited and involves dynamic interactions and T cell cooperativity. *Immunity.* 2016;44(2):233–45.
40. Oduro JD, Redeker A, Lemmermann NA, Ebermann L, Marandu TF, Dekhtiarenko I, et al. Murine cytomegalovirus infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection. *J Gen Virol.* 2016;97(1):185–95.
41. Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA, Graham BS. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. *Mucosal Immunol.* 2017;10(2):545–54.
42. Galvez-Cancino F, Lopez E, Menares E, Diaz X, Flores C, Caceres P, et al. Vaccination-induced skin-resident memory CD8(+) T cells mediate strong protection against cutaneous melanoma. *Oncoimmunology.* 2018;7(7): e1442163.
43. Redeker A, Remmerswaal EBM, van der Gracht ETI, Welten SPM, Holtt T, Koning F, et al. The contribution of cytomegalovirus infection to immune senescence is set by the infectious dose. *Front Immunol.* 2017;8:1953.
44. Pardieck IN, Beyrend G, Redeker A, Arens R. Cytomegalovirus infection and progressive differentiation of effector-memory T cells. *F1000Res.* 2018;7:1554.
45. Appay V, Dunbar PR, Callan M, Klennerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nat Med.* 2002;8(4):379–85.
46. Redeker A, Welten SP, Arens R. Viral inoculum dose impacts memory T-cell inflation. *Eur J Immunol.* 2014;44(4):1046–57.
47. Bale JF Jr, Petheram SJ, Souza IE, Murph JR. Cytomegalovirus reinfection in young children. *J Pediatr.* 1996;128(3):347–52.
48. Gorzer I, Kerschner H, Redlberger-Fritz M, Puchhammer-Stockl E. Human cytomegalovirus (HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. *J Clin Virol.* 2010;48(2):100–3.
49. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. *Science.* 2010;328(5974):102–6.
50. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. *Nat Med.* 2009;15(3):293–9.
51. Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, et al. Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. *Science.* 2016;351(6274):714–20.
52. Murray SE, Nesterenko PA, Vanarsdall AL, Munks MW, Smart SM, Veziroglu EM, et al. Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans. *J Exp Med.* 2017; 31(20161988):20161988.
53. Wang X, Messerle M, Sapinoro R, Santos K, Hocknell PK, Jin X, et al. Murine cytomegalovirus abortively infects human dendritic cells, leading to expression and presentation of virally vectored genes. *J Virol.* 2003;77(13): 7182–92.
54. Tang Q, Maul GG. Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins. *J Virol.* 2006; 80(15):7510–21.
55. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. *Vaccine.* 2001;19(27):3652–60.
56. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulvar and vaginal intraepithelial neoplasia. *Clin Cancer Res.* 2003;9(14):5205–13.
57. Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, et al. Intratumoral injection of therapeutic HPV vaccine following cisplatin enhances HPV-specific antitumor effects. *Cancer Immunol Immunother.* 2013;62(7): 1175–85.
58. Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haeffliger D, Swartz MA, et al. Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. *Cancer Immunol Res.* 2018;6(11):1301–13.
59. Peng S, Qiu J, Yang A, Yang B, Jeang J, Wang JW, et al. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease. *Cell Bioscience.* 2016;6:16.
60. Domingos-Pereira S, Derre L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, et al. Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. *J Urol.* 2014;191(3):814–22.
61. Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. *J Exp Med.* 2010;207(6):1333–43.
62. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med.* 2009;361(19):1838–47.
63. van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, et al. vaccination against Oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. *Clin Cancer Res.* 2016;22(10):2342–50.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions